Aprea Therapeutics raises $3.1M in private placement priced at $1.165/unit

and together with the Pre-Funded Warrants, the “Warrants”). The combined effective offering price of each Private Placement Share and accompanying Common Warrant to be issued is $1.165 and represents the “Minimum Price” in accordance with Nasdaq Listing Rule 5635(d), for expected aggregate gross proceeds at closing of approximately $3.1 million. The closing of

On December 8, 2025, Aprea Therapeutics, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with certain accredited investors and Company insiders (the “Purchasers”), pursuant to which the Company agreed to issue and sell to the Purchasers, and the Purchasers agreed to purchase from the Company (i) 2,623,023 shares (the “Private Placement Shares”) of the Company’s Common Stock, par value $0.001 per share (“Common Stock”) or pre-funded Common Stock purchase warrants (the “Pre-Funded Warrants”) in lieu thereof, and (ii) common stock purchase warrants to purchase up to 2,623,023 shares of Common Stock (the “Warrant Shares”) at an exercise price of $1.04 per share (the “Common Warrants” and together with the Pre-Funded Warrants, the “Warrants”).

On December 8, 2025, and in connection with the Purchase Agreement, the Company entered into a customary placement agency agreement (the “Placement Agency Agreement”) with Maxim Group LLC (“Maxim”).

In connection with the Private Placement, the Company and the Purchasers entered into a Registration Rights Agreement, dated December 8, 2025 (the “Registration Rights Agreement”), providing for the registration for resale of Private Placement Shares along with the shares of Common Stock underlying the Pre-Funded Warrants, and Common Warrants that are not then registered on an effective registration statement, pursuant to a registration statement (the “Registration Statement”) to be filed with the Securities and Exchange Commission (the “SEC”) on or prior to the 20 th day after the Closing Date.